REGN1908‐1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics

REGN1908‐1909, a 1:1 cocktail of two fully human IgG4 monoclonal antibodies (mAbs), REGN1908 and REGN1909, is being evaluated for treatment of cat allergy. Both REGN1908 and REGN1909 bind to the dominant cat allergen, Fel d 1. Adults with cat allergy confirmed by skin prick test (SPT) were randomize...

Full description

Saved in:
Bibliographic Details
Published inClinical and translational science Vol. 14; no. 6; pp. 2440 - 2449
Main Authors Kamal, Mohamed A., Dingman, Robert, Wang, Claire Q., Lai, Ching‐Ha, Rajadhyaksha, Manoj, DeVeaux, Michelle, Orengo, Jamie M., Radin, Allen, Davis, John D.
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.11.2021
John Wiley and Sons Inc
Wiley
Subjects
Adolescent
Adult
Adverse events
Allergens
Allergens - drug effects
Allergens - immunology
Allergies
Anaphylaxis
Animals
Anti-Allergic Agents - pharmacology
Anti-Allergic Agents - therapeutic use
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - pharmacokinetics
Antibodies, Monoclonal - pharmacology
Asthma
Cats
Degranulation
Double-Blind Method
Drug dosages
Enzymes
Ethics
Female
Humans
Hypersensitivity - drug therapy
Immunization
Immunoglobulin E
Immunoglobulin G
Immunotherapy
Injections
Laboratories
Male
Middle Aged
Monoclonal antibodies
Passive cutaneous anaphylaxis
Pharmacodynamics
Pharmacokinetics
Skin tests
Translation
Young Adult
United States > US
Online AccessGet full text

Cover

Abstract REGN1908‐1909, a 1:1 cocktail of two fully human IgG4 monoclonal antibodies (mAbs), REGN1908 and REGN1909, is being evaluated for treatment of cat allergy. Both REGN1908 and REGN1909 bind to the dominant cat allergen, Fel d 1. Adults with cat allergy confirmed by skin prick test (SPT) were randomized to single subcutaneous administration of placebo (n = 6) or REGN1908‐1909 at doses of 150 (n = 6), 300 (n = 6), or 600 mg (n = 6). Blood samples were taken at prespecified time points for pharmacokinetic (PK) analysis and exploratory evaluation of biomarkers (IgE and SPT). Safety was assessed. Drug concentration‐time profiles in serum for ascending doses of REGN1908‐1909 were consistent with linear PKs. Noncompartmental analysis showed that maximum concentration (Cmax) and exposure increased proportionately with dose, with similar time to maximum concentration (Tmax) for REGN1908 and REGN1909 (6.2 to 8.2 days across doses), and a longer terminal half‐life for REGN1908 (~ 30 days) relative to REGN1909 (~ 21 days). Adverse events were not dose dependent; there were no dose‐limiting toxicities. REGN1908‐1909 is characterized by linear and dose‐proportional kinetics of the two individual mAb components. A single 600 mg dose maintains total mAb mean concentrations in serum above the target (mean of ~ 10 mg/L) for 8–12 weeks. Maintaining this mean target concentration resulted in translational pharmacodynamic effects: maximal mast cell degranulation in a passive cutaneous anaphylaxis mouse model, and maintenance of clinical efficacy measured by Total Nasal Symptom Score in a previous proof‐of‐mechanism study.
AbstractList REGN1908-1909, a 1:1 cocktail of two fully human IgG4 monoclonal antibodies (mAbs), REGN1908 and REGN1909, is being evaluated for treatment of cat allergy. Both REGN1908 and REGN1909 bind to the dominant cat allergen, Fel d 1. Adults with cat allergy confirmed by skin prick test (SPT) were randomized to single subcutaneous administration of placebo (n = 6) or REGN1908-1909 at doses of 150 (n = 6), 300 (n = 6), or 600 mg (n = 6). Blood samples were taken at prespecified time points for pharmacokinetic (PK) analysis and exploratory evaluation of biomarkers (IgE and SPT). Safety was assessed. Drug concentration-time profiles in serum for ascending doses of REGN1908-1909 were consistent with linear PKs. Noncompartmental analysis showed that maximum concentration (Cmax ) and exposure increased proportionately with dose, with similar time to maximum concentration (Tmax ) for REGN1908 and REGN1909 (6.2 to 8.2 days across doses), and a longer terminal half-life for REGN1908 (~ 30 days) relative to REGN1909 (~ 21 days). Adverse events were not dose dependent; there were no dose-limiting toxicities. REGN1908-1909 is characterized by linear and dose-proportional kinetics of the two individual mAb components. A single 600 mg dose maintains total mAb mean concentrations in serum above the target (mean of ~ 10 mg/L) for 8-12 weeks. Maintaining this mean target concentration resulted in translational pharmacodynamic effects: maximal mast cell degranulation in a passive cutaneous anaphylaxis mouse model, and maintenance of clinical efficacy measured by Total Nasal Symptom Score in a previous proof-of-mechanism study.REGN1908-1909, a 1:1 cocktail of two fully human IgG4 monoclonal antibodies (mAbs), REGN1908 and REGN1909, is being evaluated for treatment of cat allergy. Both REGN1908 and REGN1909 bind to the dominant cat allergen, Fel d 1. Adults with cat allergy confirmed by skin prick test (SPT) were randomized to single subcutaneous administration of placebo (n = 6) or REGN1908-1909 at doses of 150 (n = 6), 300 (n = 6), or 600 mg (n = 6). Blood samples were taken at prespecified time points for pharmacokinetic (PK) analysis and exploratory evaluation of biomarkers (IgE and SPT). Safety was assessed. Drug concentration-time profiles in serum for ascending doses of REGN1908-1909 were consistent with linear PKs. Noncompartmental analysis showed that maximum concentration (Cmax ) and exposure increased proportionately with dose, with similar time to maximum concentration (Tmax ) for REGN1908 and REGN1909 (6.2 to 8.2 days across doses), and a longer terminal half-life for REGN1908 (~ 30 days) relative to REGN1909 (~ 21 days). Adverse events were not dose dependent; there were no dose-limiting toxicities. REGN1908-1909 is characterized by linear and dose-proportional kinetics of the two individual mAb components. A single 600 mg dose maintains total mAb mean concentrations in serum above the target (mean of ~ 10 mg/L) for 8-12 weeks. Maintaining this mean target concentration resulted in translational pharmacodynamic effects: maximal mast cell degranulation in a passive cutaneous anaphylaxis mouse model, and maintenance of clinical efficacy measured by Total Nasal Symptom Score in a previous proof-of-mechanism study.
REGN1908‐1909, a 1:1 cocktail of two fully human IgG 4 monoclonal antibodies (mAbs), REGN1908 and REGN1909, is being evaluated for treatment of cat allergy. Both REGN1908 and REGN1909 bind to the dominant cat allergen, Fel d 1. Adults with cat allergy confirmed by skin prick test (SPT) were randomized to single subcutaneous administration of placebo ( n  = 6) or REGN1908‐1909 at doses of 150 ( n  = 6), 300 ( n  = 6), or 600 mg ( n  = 6). Blood samples were taken at prespecified time points for pharmacokinetic (PK) analysis and exploratory evaluation of biomarkers (IgE and SPT). Safety was assessed. Drug concentration‐time profiles in serum for ascending doses of REGN1908‐1909 were consistent with linear PKs. Noncompartmental analysis showed that maximum concentration (C max ) and exposure increased proportionately with dose, with similar time to maximum concentration (T max ) for REGN1908 and REGN1909 (6.2 to 8.2 days across doses), and a longer terminal half‐life for REGN1908 (~ 30 days) relative to REGN1909 (~ 21 days). Adverse events were not dose dependent; there were no dose‐limiting toxicities. REGN1908‐1909 is characterized by linear and dose‐proportional kinetics of the two individual mAb components. A single 600 mg dose maintains total mAb mean concentrations in serum above the target (mean of ~ 10 mg/L) for 8–12 weeks. Maintaining this mean target concentration resulted in translational pharmacodynamic effects: maximal mast cell degranulation in a passive cutaneous anaphylaxis mouse model, and maintenance of clinical efficacy measured by Total Nasal Symptom Score in a previous proof‐of‐mechanism study.
Abstract REGN1908‐1909, a 1:1 cocktail of two fully human IgG4 monoclonal antibodies (mAbs), REGN1908 and REGN1909, is being evaluated for treatment of cat allergy. Both REGN1908 and REGN1909 bind to the dominant cat allergen, Fel d 1. Adults with cat allergy confirmed by skin prick test (SPT) were randomized to single subcutaneous administration of placebo (n = 6) or REGN1908‐1909 at doses of 150 (n = 6), 300 (n = 6), or 600 mg (n = 6). Blood samples were taken at prespecified time points for pharmacokinetic (PK) analysis and exploratory evaluation of biomarkers (IgE and SPT). Safety was assessed. Drug concentration‐time profiles in serum for ascending doses of REGN1908‐1909 were consistent with linear PKs. Noncompartmental analysis showed that maximum concentration (Cmax) and exposure increased proportionately with dose, with similar time to maximum concentration (Tmax) for REGN1908 and REGN1909 (6.2 to 8.2 days across doses), and a longer terminal half‐life for REGN1908 (~ 30 days) relative to REGN1909 (~ 21 days). Adverse events were not dose dependent; there were no dose‐limiting toxicities. REGN1908‐1909 is characterized by linear and dose‐proportional kinetics of the two individual mAb components. A single 600 mg dose maintains total mAb mean concentrations in serum above the target (mean of ~ 10 mg/L) for 8–12 weeks. Maintaining this mean target concentration resulted in translational pharmacodynamic effects: maximal mast cell degranulation in a passive cutaneous anaphylaxis mouse model, and maintenance of clinical efficacy measured by Total Nasal Symptom Score in a previous proof‐of‐mechanism study.
REGN1908‐1909, a 1:1 cocktail of two fully human IgG4 monoclonal antibodies (mAbs), REGN1908 and REGN1909, is being evaluated for treatment of cat allergy. Both REGN1908 and REGN1909 bind to the dominant cat allergen, Fel d 1. Adults with cat allergy confirmed by skin prick test (SPT) were randomized to single subcutaneous administration of placebo (n = 6) or REGN1908‐1909 at doses of 150 (n = 6), 300 (n = 6), or 600 mg (n = 6). Blood samples were taken at prespecified time points for pharmacokinetic (PK) analysis and exploratory evaluation of biomarkers (IgE and SPT). Safety was assessed. Drug concentration‐time profiles in serum for ascending doses of REGN1908‐1909 were consistent with linear PKs. Noncompartmental analysis showed that maximum concentration (Cmax) and exposure increased proportionately with dose, with similar time to maximum concentration (Tmax) for REGN1908 and REGN1909 (6.2 to 8.2 days across doses), and a longer terminal half‐life for REGN1908 (~ 30 days) relative to REGN1909 (~ 21 days). Adverse events were not dose dependent; there were no dose‐limiting toxicities. REGN1908‐1909 is characterized by linear and dose‐proportional kinetics of the two individual mAb components. A single 600 mg dose maintains total mAb mean concentrations in serum above the target (mean of ~ 10 mg/L) for 8–12 weeks. Maintaining this mean target concentration resulted in translational pharmacodynamic effects: maximal mast cell degranulation in a passive cutaneous anaphylaxis mouse model, and maintenance of clinical efficacy measured by Total Nasal Symptom Score in a previous proof‐of‐mechanism study.
REGN1908-1909, a 1:1 cocktail of two fully human IgG monoclonal antibodies (mAbs), REGN1908 and REGN1909, is being evaluated for treatment of cat allergy. Both REGN1908 and REGN1909 bind to the dominant cat allergen, Fel d 1. Adults with cat allergy confirmed by skin prick test (SPT) were randomized to single subcutaneous administration of placebo (n = 6) or REGN1908-1909 at doses of 150 (n = 6), 300 (n = 6), or 600 mg (n = 6). Blood samples were taken at prespecified time points for pharmacokinetic (PK) analysis and exploratory evaluation of biomarkers (IgE and SPT). Safety was assessed. Drug concentration-time profiles in serum for ascending doses of REGN1908-1909 were consistent with linear PKs. Noncompartmental analysis showed that maximum concentration (C ) and exposure increased proportionately with dose, with similar time to maximum concentration (T ) for REGN1908 and REGN1909 (6.2 to 8.2 days across doses), and a longer terminal half-life for REGN1908 (~ 30 days) relative to REGN1909 (~ 21 days). Adverse events were not dose dependent; there were no dose-limiting toxicities. REGN1908-1909 is characterized by linear and dose-proportional kinetics of the two individual mAb components. A single 600 mg dose maintains total mAb mean concentrations in serum above the target (mean of ~ 10 mg/L) for 8-12 weeks. Maintaining this mean target concentration resulted in translational pharmacodynamic effects: maximal mast cell degranulation in a passive cutaneous anaphylaxis mouse model, and maintenance of clinical efficacy measured by Total Nasal Symptom Score in a previous proof-of-mechanism study.
REGN1908‐1909, a 1:1 cocktail of two fully human IgG4 monoclonal antibodies (mAbs), REGN1908 and REGN1909, is being evaluated for treatment of cat allergy. Both REGN1908 and REGN1909 bind to the dominant cat allergen, Fel d 1. Adults with cat allergy confirmed by skin prick test (SPT) were randomized to single subcutaneous administration of placebo (n = 6) or REGN1908‐1909 at doses of 150 (n = 6), 300 (n = 6), or 600 mg (n = 6). Blood samples were taken at prespecified time points for pharmacokinetic (PK) analysis and exploratory evaluation of biomarkers (IgE and SPT). Safety was assessed. Drug concentration‐time profiles in serum for ascending doses of REGN1908‐1909 were consistent with linear PKs. Noncompartmental analysis showed that maximum concentration (Cmax) and exposure increased proportionately with dose, with similar time to maximum concentration (Tmax) for REGN1908 and REGN1909 (6.2 to 8.2 days across doses), and a longer terminal half‐life for REGN1908 (~ 30 days) relative to REGN1909 (~ 21 days). Adverse events were not dose dependent; there were no dose‐limiting toxicities. REGN1908‐1909 is characterized by linear and dose‐proportional kinetics of the two individual mAb components. A single 600 mg dose maintains total mAb mean concentrations in serum above the target (mean of ~ 10 mg/L) for 8–12 weeks. Maintaining this mean target concentration resulted in translational pharmacodynamic effects: maximal mast cell degranulation in a passive cutaneous anaphylaxis mouse model, and maintenance of clinical efficacy measured by Total Nasal Symptom Score in a previous proof‐of‐mechanism study.
Author Davis, John D.
Wang, Claire Q.
Rajadhyaksha, Manoj
DeVeaux, Michelle
Dingman, Robert
Orengo, Jamie M.
Kamal, Mohamed A.
Radin, Allen
Lai, Ching‐Ha
AuthorAffiliation 1 Regeneron Pharmaceuticals Tarrytown NY USA
AuthorAffiliation_xml – name: 1 Regeneron Pharmaceuticals Tarrytown NY USA
Author_xml – sequence: 1
  givenname: Mohamed A.
  surname: Kamal
  fullname: Kamal, Mohamed A.
  email: mohamed.kamal@regeneron.com
  organization: Regeneron Pharmaceuticals
– sequence: 2
  givenname: Robert
  surname: Dingman
  fullname: Dingman, Robert
  organization: Regeneron Pharmaceuticals
– sequence: 3
  givenname: Claire Q.
  surname: Wang
  fullname: Wang, Claire Q.
  organization: Regeneron Pharmaceuticals
– sequence: 4
  givenname: Ching‐Ha
  surname: Lai
  fullname: Lai, Ching‐Ha
  organization: Regeneron Pharmaceuticals
– sequence: 5
  givenname: Manoj
  surname: Rajadhyaksha
  fullname: Rajadhyaksha, Manoj
  organization: Regeneron Pharmaceuticals
– sequence: 6
  givenname: Michelle
  surname: DeVeaux
  fullname: DeVeaux, Michelle
  organization: Regeneron Pharmaceuticals
– sequence: 7
  givenname: Jamie M.
  surname: Orengo
  fullname: Orengo, Jamie M.
  organization: Regeneron Pharmaceuticals
– sequence: 8
  givenname: Allen
  surname: Radin
  fullname: Radin, Allen
  organization: Regeneron Pharmaceuticals
– sequence: 9
  givenname: John D.
  surname: Davis
  fullname: Davis, John D.
  organization: Regeneron Pharmaceuticals
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34437752$$D View this record in MEDLINE/PubMed
BookMark eNp1ks1uEzEQx1eoiH7AgRdAK3GBQ1p_75oDEoraUqkCCcLZGnu9qVOvXewNKDd4A56RJ8FN0ohW4MtYM__5-S_PHFZ7IQZbVc8xOsblnJgxH2OKMXlUHeCGk0mLBNnb3Tnbrw5zXiAkqGj5k2qfMkabUjyofn46Pf-AJWp___hVgqyHGKLxMYCvIYxOx87ZXGsfzXV9Zn3d1bh2oTYw1uC9TXNn6rzUC1tMvKlnCUL2MLo14OYK0gAmXrtgR2dyIXa7ZLcKMJTk0-pxDz7bZ9t4VH05O51N308uP55fTN9dTgxHkkyg6yUlqJekJwCkEQCCCdwLTTXnhPWCGmp7YzujpUVcy8bKjrLWYI1pi-hRdbHhdhEW6ia5AdJKRXBqnYhpriAVl94qIXshGrC67TXTtNEtF9IIy6EDYKwtrLcb1s1SD-VFG8YE_h70fiW4KzWP31QrECOUFMCrLSDFr0ubRzW4bKz3EGxcZkW4EIgyKnmRvnwgXcRlKt97q5JlZC1ntKhe_O1oZ-Vu0kVwshGYFHNOtlfGjetBFYPOK4zU7S6pMka13qXS8fpBxx30X9ot_bvzdvV_oZrOPm86_gD3-tog
CitedBy_id crossref_primary_10_3390_jcm12082848
crossref_primary_10_1016_j_jaci_2022_06_025
crossref_primary_10_1080_1744666X_2023_2209319
crossref_primary_10_3389_fimmu_2023_1339171
crossref_primary_10_3389_fimmu_2024_1343024
crossref_primary_10_3390_ijms25147602
crossref_primary_10_3390_biomedicines10092330
crossref_primary_10_1007_s15007_023_5766_z
crossref_primary_10_1007_s40629_023_00254_9
crossref_primary_10_1002_clt2_12274
crossref_primary_10_1111_vde_13291
crossref_primary_10_1111_all_15659
crossref_primary_10_3389_falgy_2022_1019255
Cites_doi 10.1084/jem.62.6.733
10.1016/j.jaci.2009.03.011
10.2165/11537430-000000000-00000
10.1016/j.jaci.2017.10.010
10.1016/j.jaci.2013.12.1071
10.1038/nm.2755
10.1186/s40413-015-0063-2
10.1097/01.all.0000136753.35948.c0
10.1111/j.1398-9995.2010.02474.x
10.1159/000250435
10.1111/all.13805
10.1111/j.1398-9995.2011.02745.x
10.1097/ACI.0000000000000457
10.1164/rccm.202011-4107OC
10.1016/S0091-6749(99)70017-5
10.1016/j.jaci.2005.06.004
10.1038/s41467-018-03636-8
ContentType Journal Article
Copyright 2021 Regeneron Pharmaceuticals, Inc. published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.
2021 Regeneron Pharmaceuticals, Inc. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.
2021. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2021 Regeneron Pharmaceuticals, Inc. published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.
– notice: 2021 Regeneron Pharmaceuticals, Inc. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.
– notice: 2021. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QP
7T5
7TK
7TM
7U9
7X7
7XB
8FD
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M7N
M7P
P64
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
RC3
7X8
5PM
DOA
DOI 10.1111/cts.13112
DatabaseName Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
Biological Science Collection
ProQuest Central (New)
Natural Science Collection
ProQuest One
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
Genetics Abstracts
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Immunology Abstracts
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

CrossRef


MEDLINE
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate REGN1908‐1909 pharmacokinetics/pharmacodynamics
EISSN 1752-8062
EndPage 2449
ExternalDocumentID oai_doaj_org_article_69f667aeb8fb4b37b8569c6e5adaa448
PMC8604232
34437752
10_1111_cts_13112
CTS13112
Genre article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GrantInformation_xml – fundername: Regeneron Pharmaceuticals
– fundername: ;
GroupedDBID ---
05W
0R~
10A
1OC
24P
29B
31~
4.4
52S
53G
5GY
5VS
7X7
8-1
8FE
8FH
8FI
8FJ
AAHHS
AANHP
AAZKR
ABDBF
ABUWG
ACBWZ
ACCFJ
ACCMX
ACRPL
ACUHS
ACXQS
ACYXJ
ADKYN
ADNMO
ADZMN
ADZOD
AEEZP
AEQDE
AFBPY
AFKRA
AFZJQ
AIWBW
AJBDE
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AVUZU
BBNVY
BDRZF
BENPR
BHPHI
BPHCQ
BRXPI
BVXVI
CAG
CCPQU
COF
CS3
DIK
EBD
EBS
EJD
EMOBN
ESX
F5P
FEDTE
FYUFA
G-S
GODZA
GROUPED_DOAJ
HCIFZ
HMCUK
HVGLF
HYE
HZ~
IAO
IHR
ITC
KQ8
LH4
LK8
LW6
M7P
MY~
O9-
OIG
OK1
P2P
PIMPY
PQQKQ
PROAC
QB0
ROL
RPM
SUPJJ
SV3
TUS
UKHRP
WIN
XG1
AAYXX
AGQPQ
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QP
7T5
7TK
7TM
7U9
7XB
8FD
8FK
AZQEC
DWQXO
FR3
GNUQQ
H94
K9.
M7N
P64
PKEHL
PQEST
PQGLB
PQUKI
PRINS
RC3
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c5092-adf9320f92f2aa276aa6461f6b3b5524f63c3efcedcb9e05b97e9d348c1b13803
IEDL.DBID 7X7
ISSN 1752-8054
1752-8062
IngestDate Wed Aug 27 01:22:28 EDT 2025
Thu Aug 21 18:36:28 EDT 2025
Fri Jul 11 16:19:39 EDT 2025
Sat Aug 23 13:46:27 EDT 2025
Wed Feb 19 02:27:22 EST 2025
Tue Jul 01 01:05:37 EDT 2025
Thu Apr 24 23:09:15 EDT 2025
Wed Jan 22 16:28:36 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
License Attribution-NonCommercial-NoDerivs
2021 Regeneron Pharmaceuticals, Inc. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5092-adf9320f92f2aa276aa6461f6b3b5524f63c3efcedcb9e05b97e9d348c1b13803
Notes Funding information
Trial registration
clinicaltrials.gov NCT01922661
This study was funded by Regeneron Pharmaceuticals.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
Trial registration: clinicaltrials.gov NCT01922661
OpenAccessLink https://www.proquest.com/docview/2599098543?pq-origsite=%requestingapplication%
PMID 34437752
PQID 2599098543
PQPubID 2029979
PageCount 9
ParticipantIDs doaj_primary_oai_doaj_org_article_69f667aeb8fb4b37b8569c6e5adaa448
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8604232
proquest_miscellaneous_2566034395
proquest_journals_2599098543
pubmed_primary_34437752
crossref_citationtrail_10_1111_cts_13112
crossref_primary_10_1111_cts_13112
wiley_primary_10_1111_cts_13112_CTS13112
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate November 2021
PublicationDateYYYYMMDD 2021-11-01
PublicationDate_xml – month: 11
  year: 2021
  text: November 2021
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle Clinical and translational science
PublicationTitleAlternate Clin Transl Sci
PublicationYear 2021
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
– name: Wiley
References 1935; 62
2010; 65
2018; 18
2018; 9
2019; 74
2021; 204
2005; 116
2011; 50
2004; 4
2009; 123
2007
2018
2017; 140
2012; 18
2010; 151
1999; 104
2015; 8
2012; 67
2014; 134
e_1_2_10_12_1
e_1_2_10_9_1
e_1_2_10_13_1
e_1_2_10_10_1
e_1_2_10_11_1
e_1_2_10_20_1
e_1_2_10_2_1
e_1_2_10_4_1
e_1_2_10_18_1
e_1_2_10_3_1
e_1_2_10_19_1
e_1_2_10_6_1
e_1_2_10_16_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_8_1
e_1_2_10_14_1
e_1_2_10_7_1
e_1_2_10_15_1
References_xml – volume: 104
  start-page: 1223
  year: 1999
  end-page: 1230
  article-title: Purified natural and recombinant Fel d 1 and cat albumin in in vitro diagnostics for cat allergy
  publication-title: J Allergy Clin Immunol
– volume: 4
  start-page: 313
  year: 2004
  end-page: 318
  article-title: Mechanisms of immunotherapy: IgG revisited
  publication-title: Curr Opin Allergy Clin Immunol
– volume: 204
  start-page: 23
  issue: 1
  year: 2021
  end-page: 33
  article-title: Passive immunotherapy with single‐dose of anti‐Fel d 1 monoclonal antibodies REGN1908‐1909 in cat allergen‐induced allergic rhinitis
  publication-title: Am J Respir Crit Care Med
– volume: 134
  start-page: 350
  year: 2014
  end-page: 359
  article-title: Prevalence of allergic sensitization in the United States: results from the National Health and Nutrition Examination Survey (NHANES) 2005–2006
  publication-title: J Allergy Clin Immunol
– volume: 65
  start-page: 1525
  year: 2010
  end-page: 1530
  article-title: GA(2) LEN/EAACI pocket guide for allergen‐specific immunotherapy for allergic rhinitis and asthma
  publication-title: Allergy
– volume: 8
  start-page: 17
  year: 2015
  article-title: Mechanisms of allergen‐specific immunotherapy and immune tolerance to allergens
  publication-title: World Allergy Organ J
– volume: 9
  start-page: 1421
  year: 2018
  article-title: Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement
  publication-title: Nat Commun
– volume: 151
  start-page: 265
  year: 2010
  end-page: 274
  article-title: The major cat allergen, Fel d 1, in diagnosis and therapy
  publication-title: Int Arch Allergy Immunol
– volume: 50
  start-page: 131
  year: 2011
  end-page: 142
  article-title: Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first‐in‐human prediction
  publication-title: Clin Pharmacokinet
– year: 2007
– volume: 18
  start-page: 350
  year: 2018
  end-page: 355
  article-title: Does evidence support the use of cat allergen immunotherapy?
  publication-title: Curr Opin Allergy Clin Immunol
– volume: 18
  start-page: 693
  year: 2012
  end-page: 704
  article-title: IgE and mast cells in allergic disease
  publication-title: Nat Med
– volume: 62
  start-page: 733
  year: 1935
  end-page: 750
  article-title: Serological evidence of immunity with coexisting sensitization in a type of human allergy (Hay Fever)
  publication-title: J Exp Med
– volume: 116
  start-page: 608
  year: 2005
  end-page: 613
  article-title: Allergen‐specific immunotherapy with recombinant grass pollen allergens
  publication-title: J Allergy Clin Immunol
– volume: 67
  start-page: 217
  year: 2012
  end-page: 226
  article-title: Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy
  publication-title: Allergy
– volume: 140
  start-page: 1485
  year: 2017
  end-page: 1498
  article-title: Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers
  publication-title: J Allergy Clin Immunol
– volume: 74
  start-page: 2087
  year: 2019
  end-page: 2102
  article-title: 2019 ARIA Care pathways for allergen immunotherapy
  publication-title: Allergy
– year: 2018
– volume: 123
  start-page: 1189
  year: 2009
  end-page: 1191
  article-title: The carbohydrate galactose‐alpha‐1,3‐galactose is a major IgE‐binding epitope on cat IgA
  publication-title: J Allergy Clin Immunol
– ident: e_1_2_10_15_1
  doi: 10.1084/jem.62.6.733
– ident: e_1_2_10_16_1
  doi: 10.1016/j.jaci.2009.03.011
– ident: e_1_2_10_19_1
  doi: 10.2165/11537430-000000000-00000
– ident: e_1_2_10_8_1
  doi: 10.1016/j.jaci.2017.10.010
– ident: e_1_2_10_18_1
– ident: e_1_2_10_2_1
  doi: 10.1016/j.jaci.2013.12.1071
– ident: e_1_2_10_20_1
  doi: 10.1038/nm.2755
– ident: e_1_2_10_7_1
  doi: 10.1186/s40413-015-0063-2
– ident: e_1_2_10_5_1
  doi: 10.1097/01.all.0000136753.35948.c0
– ident: e_1_2_10_9_1
  doi: 10.1111/j.1398-9995.2010.02474.x
– ident: e_1_2_10_4_1
  doi: 10.1159/000250435
– ident: e_1_2_10_17_1
– ident: e_1_2_10_10_1
  doi: 10.1111/all.13805
– ident: e_1_2_10_13_1
  doi: 10.1111/j.1398-9995.2011.02745.x
– ident: e_1_2_10_11_1
  doi: 10.1097/ACI.0000000000000457
– ident: e_1_2_10_14_1
  doi: 10.1164/rccm.202011-4107OC
– ident: e_1_2_10_3_1
  doi: 10.1016/S0091-6749(99)70017-5
– ident: e_1_2_10_6_1
  doi: 10.1016/j.jaci.2005.06.004
– ident: e_1_2_10_12_1
  doi: 10.1038/s41467-018-03636-8
SSID ssj0063685
Score 2.3234851
Snippet REGN1908‐1909, a 1:1 cocktail of two fully human IgG4 monoclonal antibodies (mAbs), REGN1908 and REGN1909, is being evaluated for treatment of cat allergy....
REGN1908‐1909, a 1:1 cocktail of two fully human IgG 4 monoclonal antibodies (mAbs), REGN1908 and REGN1909, is being evaluated for treatment of cat allergy....
REGN1908-1909, a 1:1 cocktail of two fully human IgG monoclonal antibodies (mAbs), REGN1908 and REGN1909, is being evaluated for treatment of cat allergy. Both...
REGN1908-1909, a 1:1 cocktail of two fully human IgG4 monoclonal antibodies (mAbs), REGN1908 and REGN1909, is being evaluated for treatment of cat allergy....
Abstract REGN1908‐1909, a 1:1 cocktail of two fully human IgG4 monoclonal antibodies (mAbs), REGN1908 and REGN1909, is being evaluated for treatment of cat...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2440
SubjectTerms Adolescent
Adult
Adverse events
Allergens
Allergens - drug effects
Allergens - immunology
Allergies
Anaphylaxis
Animals
Anti-Allergic Agents - pharmacology
Anti-Allergic Agents - therapeutic use
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - pharmacokinetics
Antibodies, Monoclonal - pharmacology
Asthma
Cats
Degranulation
Double-Blind Method
Drug dosages
Enzymes
Ethics
Female
Humans
Hypersensitivity - drug therapy
Immunization
Immunoglobulin E
Immunoglobulin G
Immunotherapy
Injections
Laboratories
Male
Middle Aged
Monoclonal antibodies
Passive cutaneous anaphylaxis
Pharmacodynamics
Pharmacokinetics
Skin tests
Translation
Young Adult
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQD4gL4p-Uggzi0Esg8V9sblB1qZDoAVqpt8jj2GLVVbZqdu_tG_CMPAljxxt1RREXTokSJ7Fnxp7P8fgbQt5KDU6AkqUy3pSiE7q0lelKBoKLELfB2hRtcayOTsWXM3l2I9VXjAkb6YFHwb1XJijVWA86gADegJbKOOWl7azFuUUcfdHnbSZT4xisIq162gopsb8jKsmcQjGGx62Gd5Fjhm15okTYfxvK_DNY8iaITV5o9oDcz_CRfhyr_ZDc8f0jcvdrXiB_TK6_HX4-Ru-rf139xIOhaGVLt4hwm6IM57CMUYMU0IWd05lf0I7WdN5TZ1c0ZlW5xIGQDmuIf2eGDzR5skX-X0gvMs31OX4qsjvjG7vpYjemth-ekNPZ4cnBUZmzLJQOwQIrbRcQw1XBsMCsZY2yVglVBwUcpGQiKO64Dw4lAMZXEkzjTceFdjXUXFf8Kdnpl71_Tig3IBhztZUIKn1Q6Pk4BMmi7pjVUJD9jcRblynIYyaMRbuZimDb2qScgryZil6MvBu3FfoU1TYViFTZ6QIaUJsNqP2XARVkb6P0NvffocVJIepIS8EL8nq6jT0vLqfY3i_XsYxSFUdAJwvybLSRqSZcCN6g8RWk2bKerapu3-nnPxK7t1YxVAmf3E929vfWtwcn39PJ7v8Qwwtyj8VwnbTNco_srC7X_iXirRW8Sl3rN8UcKWU
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Wiley Online Library Open Access
  dbid: 24P
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELaqIiEuiDehBRnEoZegrF-x4QRVlwqJCkEr9RbZjg2rrpJqs3sv_4DfyC9hxnmoK4rEKVE8SRzPjOezM_5MyGupnRdOyVyZYHJRC53bwtQ5c4KLiMtgbcq2OFHHZ-LTuTzfIe_GtTA9P8Q04YaekfprdHDrumtO7tfdG-SKgf73Fj4TifOZ-DJ2wwqZ1dNqSAkuD8BkoBXCNJ7p1q1glDj7bwKaf-dLXsexKRDN75G7A4Kk73uV3yc7oXlAbn8e_pE_JD-_Hn08gQCsf1_9goOhYGitXyLiptCMC9di4iB1EMUu6DwsaU1ndNFQb9cUN1ZZQV9Iu43DCZruLU3BbDlMGdLLgen6Al6FBM_wxHq6WPe723ePyNn86PTwOB82Wsg94AWW2zoCjCuiYZFZy0plrRJqFpXjTkomouKeh-ihBZwJhXSmDKbmQvuZm3Fd8Mdkt2mb8JRQbpxgzM-sBFwZooLgx12UzOnomNUuIwdji1d-YCHHzTCW1TgagW-rknIy8moSveypN24S-oBqmwSQLTtdaFffq8H5KmWiUqUNWAnheOm0VMarIG1tLYxPM7I_Kr0aXLirYFwIOtJS8Iy8nIrB-fCPim1Cu0EZpQoOmE5m5ElvI1NNuBC8BOPLSLllPVtV3S5pFj8SwbdWmK0Edx4kO_v311eHp9_SybP_F90jdxjm5aT1lPtkd73ahOcArNbuRXKgP3NTH_A
  priority: 102
  providerName: Wiley-Blackwell
Title REGN1908‐1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcts.13112
https://www.ncbi.nlm.nih.gov/pubmed/34437752
https://www.proquest.com/docview/2599098543
https://www.proquest.com/docview/2566034395
https://pubmed.ncbi.nlm.nih.gov/PMC8604232
https://doaj.org/article/69f667aeb8fb4b37b8569c6e5adaa448
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELbYXQlxQbwJLJVBHPYSSP1KzAWxq5YVEtVq2ZV6i2zHgWqrpDTtHf4Bv5FfwozrBioWTo0Sp_FjxvN5PP6GkJeysE5YJVOlvU5FJYrUZLpKmRVc1HgM1oRoi4k6vRQfpnIaHW5dDKvczolhoq5ahz7y1wDTdaYLKfjbxdcUs0bh7mpMobFHDpC6DEO68mm_4FJIrh4ORErQesAmkVkII3ncqnuFTDNsxx4F2v7rsObfIZN_Qtlgi8Z3yO0IIum7zajfJTd8c4_c_Bi3ye-T7-ej9xOwwcXPbz_gR1OofOvmCLop9OTMthg7SC0Ysis69nNa0SGdNdSZFcXcKkuYDmm3tuij6d7QYM_m0WtIF5Hs-go-hRzP8I9Vf7PaJLjvHpDL8eji5DSNuRZSB5CBpaaqAclltWY1M4blyhgl1LBWllspmagVd9zXDnrAap9Jq3OvKy4KN7RDXmT8Idlv2sY_JpRrKxhzQyMBWvpagf3jtpbMFrVlprAJOdr2eOkiETnmw5iX2wUJtK0Mg5OQF33RxYZ947pCxzhsfQEkzA432uXnMupfqXStVG48VkJYnttCKu2Ul6YyBpaoCTncDnoZtbgrf8tcQp73j0H_cFPFNL5dYxmlMg6wTibk0UZG-ppwIXgOwpeQfEd6dqq6-6SZfQkc34XCgCV48yjI2b9bX55cfAoXT_7fgqfkFsNwnHCM8pDsr5Zr_wzw1MoOyB4TZ4OgOgNycDyanJ0Pgm_iF5iVI2I
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dbtMwFLZGJwE3iH8CAwwCaTeB1H-JkRBio6VjW4VGJ-0u2I4N1UpS-iO0O3gDnoSH4kk4dpNCxeBuV6kcJ7Vzjs_5bB9_B6FHPNOGacFjIa2MWcGyWCWyiIlmlDl_DFaFaIu-6B2yN0f8aA39aM7C-LDKxiYGQ11Uxq-RPwWYLhOZcUZfjD_HPmuU311tUmgs1GLXnnyBKdv0-c4rkO9jQrqdwXYvrrMKxAacI4lV4QCzJE4SR5QiqVBKMNF2QlPNOWFOUEOtM7YwWtqEa5laWVCWmbZu0yyh8N5zaJ1RmMq00PpWp__2oLH9wtO5hyOYHOwMoKGay8jHDpnZ9InntiErHjAkCjgN3f4dpPkneA7er3sZXaphK3650LMraM2WV9H5_Xpj_hr6dtB53Qevn_38-h0uEsPnqszIw3wMshvqykcrYg2u8xh37QgXuI2HJTZqhn02lwkYYDyda78qNH2Ggwcd1euUeFzTax_DX3lWaXhjsSwsTkr1CQqvo8MzkcMN1Cqr0t5CmErNCDFtxQHMWifA41LtONGZ00RlOkKbzRfPTU197jNwjPJmCgR9y4NwIvRwWXW84Ps4rdKWF9uygqfoDgXV5ENej_hcSCdEqqxvBNM01RkX0gjLVaEUTIojtNEIPa_txjT_reURerC8DSPeb-Oo0lZzX0eIhAKQ5BG6udCRZUsoYzQF5YtQuqI9K01dvVMOPwZW8Uz4ECl4cjPo2b97n28P3oUft__fg_voQm-wv5fv7fR376CLxAcDhUOcG6g1m8ztXUBzM32vHkIYvT_rUfsLxZ5emw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3LbtQwFLVKkSo2iDeBAgaB1E1o4ldiJISg7dBSGCFopdmltmPDqEMyzEOoO_gDvofP4Uu49iSBEYVdV4lsJ7FzX8f29b0IPeS5NkwLHgtpZcxKlscqkWVMNKPM-WOwKnhb9MXuIXs14IMV9KM9C-PdKludGBR1WRu_Rr4JMF0mMueMbrrGLeLtdu_Z-HPsM0j5ndY2ncaCRfbtyReYvk2f7m0DrR8R0ts52NqNmwwDsQFDSWJVOsAviZPEEaVIJpQSTKROaKo5J8wJaqh1xpZGS5twLTMrS8pyk-qU5gmF955D5zPKUy9j2aCb7Akf2D0cxuSgcQAXNVGNvBeRmU0f-yg3ZMkWhpQBp-Hcv901_4TRwQ72LqGLDYDFzxccdxmt2OoKWnvTbNFfRd_e7bzsg_3Pf379DheJ4WfVZuQBPwYqDnXt_RaxBiN6jHt2hEuc4mGFjZphn9dlAqoYT-farw9Nn-BgS0fNiiUeN4G2j-FTPr40vLHsCsuTSn2Cwmvo8EyocB2tVnVlbyJMpWaEmFRxgLXWCbC9VDtOdO40UbmO0Eb7xwvTBEH3uThGRTsZgrEVgTgRetA1HS8if5zW6IUnW9fAB-sOBfXkQ9HIfiGkEyJT1neCaZrpnAtphOWqVAqmxxFab4leNBpkWvzm9wjd76pB9v2GjqpsPfdthEgoQEoeoRsLHul6QhmjGTBfhLIl7lnq6nJNNfwY4ovnwjtLwZMbgc_-Pfpi6-B9uLn1_xHcQ2sgq8Xrvf7-bXSBeK-gcJpzHa3OJnN7B2DdTN8N8oPR0VkL7C8TXWFr
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=REGN1908%E2%80%901909+monoclonal+antibodies+block+Fel+d+1+in+cat+allergic+subjects%3A+Translational+pharmacokinetics+and+pharmacodynamics&rft.jtitle=Clinical+and+translational+science&rft.au=Kamal%2C+Mohamed+A&rft.au=Dingman%2C+Robert&rft.au=Wang%2C+Claire+Q&rft.au=Ching%E2%80%90Ha+Lai&rft.date=2021-11-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=1752-8054&rft.eissn=1752-8062&rft.volume=14&rft.issue=6&rft.spage=2440&rft.epage=2449&rft_id=info:doi/10.1111%2Fcts.13112&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1752-8054&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1752-8054&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1752-8054&client=summon